Nanoparticulate fibrate formulations
View Patent ↗The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
1. A stable fenofibrate composition for oral administration comprising:
(a) particles of fenofibrate or a salt thereof having a D50 particle size of less than about 500 nm,
(b) at least one surface stabilizer, and
(c) an additional active ingredient,
wherein:
(i) the composition exhibits bioequivalence upon administration to a human subject in a fed state as compared to administration to a human subject in a fasted state; where bioequivalency is established by:
(a) a 90% Confidence Interval for AUC which is between 80% and 125%, and
(b) a 90% Confidence Interval for C max , which is between 80% and 125%;
(ii) the composition redisperses in a biorelevant media; and
(iii) the composition is phospholipid-free.
2. The composition of claim 1 , wherein the additional active ingredient is a statin or an HMG-CoA reductase inhibitor.
3. The composition of claim 2 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, simvastatin, velostatin, atorvastatin, 6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones and derivatives, fluvastatin, fluindostatin, pyrazole analogs of mevalonolactone derivatives, rivastatin, pyridyldihydroxyheptenoic acids, 3-substituted pentanedioic acid derivative, dichloroacetate, imidazole analogs of mevalonolactone, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives, 2,3-di-substituted pyrrole, furan, and thiophene derivatives, naphthyl analogs of mevalonolactone, octahydronaphthalenes, keto analogs of mevinolin, and phosphinic acid compounds.
4. The composition of claim 2 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of simvastatin and atorvastatin.
5. A stable fenofibrate composition for oral administration comprising:
(a) particles of fenofibrate or a salt thereof having a D50 particle size of less than about 500 nm in a dosage form for oral administration which is a tablet or capsule of about 145 mg of fenofibrate,
(b) at least one surface stabilizer, and
(c) an additional active ingredient,
wherein:
(i) the composition exhibits bioequivalence upon administration to a human subject in a fed state as compared to administration to a human subject in a fasted state; where bioequivalency is established by:
(a) a 90% Confidence Interval for AUC which is between 80% and 125%, and
(b) a 90% Confidence Interval for C max , which is between 80% and 125%;
(ii) the composition redisperses in a biorelevant media; and
(iii) the composition is phospholipid-free.
6. The composition of claim 5 , wherein the additional active ingredient is a statin or an HMG-CoA reductase inhibitor.
7. The composition of claim 6 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, simvastatin, velostatin, atorvastatin, 6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones and derivatives, fluvastatin, fluindostatin, pyrazole analogs of mevalonolactone derivatives, rivastatin, pyridyldihydroxyheptenoic acids, 3-substituted pentanedioic acid derivative, dichloroacetate, imidazole analogs of mevalonolactone, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives, 2,3-di-substituted pyrrole, furan, and thiophene derivatives, naphthyl analogs of mevalonolactone, octahydronaphthalenes, keto analogs of mevinolin, and phosphinic acid compounds.
8. The composition of claim 6 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of simvastatin and atorvastatin.
9. A stable fenofibrate composition for oral administration comprising:
(a) particles of fenofibrate or a salt thereof having a mean particle size of less than about 500 nm,
(b) at least one surface stabilizer, wherein the surface stabilizer is not selected from the group consisting of sorbitan esters, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters and polyoxyethylene stearates, and
(c) an additional active ingredient,
wherein:
(i) the composition exhibits bioequivalence upon administration to a human subject in a fed state as compared to administration to a human subject in a fasted state; where bioequivalency is established by:
(a) a 90% Confidence Interval for AUC which is between 80% and 125%, and
(b) a 90% Confidence Interval for C max , which is between 80% and 125%;
(ii) the composition redisperses in a biorelevant media; and
(iii) the composition is phospholipid-free.
10. The composition of claim 9 , wherein the additional active ingredient is a statin or an HMG-CoA reductase inhibitor.
11. The composition of claim 10 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, simvastatin, velostatin, atorvastatin, 6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones and derivatives, fluvastatin, fluindostatin, pyrazole analogs of mevalonolactone derivatives, rivastatin, pyridyldihydroxyheptenoic acids, 3-substituted pentanedioic acid derivative, dichloroacetate, imidazole analogs of mevalonolactone, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives, 2,3-di-substituted pyrrole, furan, and thiophene derivatives, naphthyl analogs of mevalonolactone, octahydronaphthalenes, keto analogs of mevinolin, and phosphinic acid compounds.
12. The composition of claim 10 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of simvastatin and atorvastatin.
13. A stable fenofibrate composition for oral administration comprising:
(a) particles of fenofibrate or a salt thereof having a D90 particle size of less than about 700 nm,
(b) at least one surface stabilizer, and
(c) an additional active ingredient,
wherein:
(i) the composition exhibits bioequivalence upon administration to a human subject in a fed state as compared to administration to a human subject in a fasted state; where bioequivalency is established by:
(a) a 90% Confidence Interval for AUC which is between 80% and 125%, and
(b) a 90% Confidence Interval for C max , which is between 80% and 125%;
(ii) the composition redisperses in a biorelevant media; and
(iii) the composition is phospholipid-free.
14. The composition of claim 13 , wherein the additional active ingredient is a statin or an HMG-CoA reductase inhibitor.
15. The composition of claim 14 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, simvastatin, velostatin, atorvastatin, 6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones and derivatives, fluvastatin, fluindostatin, pyrazole analogs of mevalonolactone derivatives, rivastatin, pyridyldihydroxyheptenoic acids, 3-substituted pentanedioic acid derivative, dichloroacetate, imidazole analogs of mevalonolactone, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives, 2,3-di-substituted pyrrole, furan, and thiophene derivatives, naphthyl analogs of mevalonolactone, octahydronaphthalenes, keto analogs of mevinolin, and phosphinic acid compounds.
16. The composition of claim 14 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of simvastatin and atorvastatin.
17. A stable fenofibrate composition for oral administration comprising:
(a) particles of fenofibrate or a salt thereof having a mean particle size of less than about 500 nm in a dosage form for oral administration which is a tablet or capsule of about 145 mg of fenofibrate,
(b) at least one surface stabilizer, and
(c) an additional active ingredient,
wherein:
(i) the composition exhibits bioequivalence upon administration to a human subject in a fed state as compared to administration to a human subject in a fasted state; where bioequivalency is established by:
(a) a 90% Confidence Interval for AUC which is between 80% and 125%, and
(b) a 90% Confidence Interval for C max , which is between 80% and 125%;
(ii) the composition redisperses in a biorelevant media; and
(iii) the composition is phospholipid-free.
18. The composition of claim 17 , wherein the additional active ingredient is a statin or an HMG-CoA reductase inhibitor.
19. The composition of claim 18 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, simvastatin, velostatin, atorvastatin, 6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones and derivatives, fluvastatin, fluindostatin, pyrazole analogs of mevalonolactone derivatives, rivastatin, pyridyldihydroxyheptenoic acids, 3-substituted pentanedioic acid derivative, dichloroacetate, imidazole analogs of mevalonolactone, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives, 2,3-di-substituted pyrrole, furan, and thiophene derivatives, naphthyl analogs of mevalonolactone, octahydronaphthalenes, keto analogs of mevinolin, and phosphinic acid compounds.
20. The composition of claim 18 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of simvastatin, and atorvastatin.
21. A stable fenofibrate composition for oral administration comprising:
(a) particles of fenofibrate or a salt thereof having a D90 particle size of less than about 500 nm in a dosage form for oral administration which is a tablet or capsule of about 145 mg of fenofibrate,
(b) at least one surface stabilizer, and
(c) an additional active ingredient,
wherein:
(i) the composition exhibits bioequivalence upon administration to a human subject in a fed state as compared to administration to a human subject in a fasted state; where bioequivalency is established by:
(a) a 90% Confidence Interval for AUC which is between 80% and 125%, and
(b) a 90% Confidence Interval for C max , which is between 80% and 125%;
(ii) the composition redisperses in a biorelevant media; and
(iii) the composition is phospholipid-free.
22. The composition of claim 21 , wherein the additional active ingredient is a statin or an HMG-CoA reductase inhibitor.
23. The composition of claim 22 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, simvastatin, velostatin, atorvastatin, 6[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones and derivatives, fluvastatin, fluindostatin, pyrazole analogs of mevalonolactone derivatives, rivastatin, pyridyldihydroxyheptenoic acids, 3-substituted pentanedioic acid derivative, dichloroacetate, imidazole analogs of mevalonolactone, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives, 2,3-di-substituted pyrrole, furan, and thiophene derivatives, naphthyl analogs of mevalonolactone, octahydronaphthalenes, keto analogs of mevinolin, and phosphinic acid compounds.
24. The composition of claim 22 , wherein the statin or HMG-CoA reductase inhibitor is selected from the group consisting of simvastatin and atorvastatin.
25. A method of treating a subject comprising administering to the subject an effective amount of a composition of claim 1 .
26. A method of treating a subject comprising administering to the subject an effective amount of a composition of claim 5 .
27. A method of treating a subject comprising administering to the subject an effective amount of a composition of claim 9 .
28. A method of treating a subject comprising administering to the subject an effective amount of a composition of claim 13 .
29. A method of treating a subject comprising administering to the subject an effective amount of a composition of claim 17 .
30. A method of treating a subject comprising administering to the subject an effective amount of a composition of claim 21 .